After a number of successes in various companies, Wim Van Criekinge and Jan Van den Berghe have founded Novalis (www.noval.is)

Novalis is an incubator for biotech and life sciences related companies, made possible by the unique combination of our contacts and experience and our complementary skills

We have raised several million euros. Our first portfolio companies have already started!

For those of you who have time, here is a little shout out to Georg Philipp Friedrich Freiherr von Hardenberg, the original “Novalis”!

News

Epify Strengthens Management Team by Appointing Leander Van Neste as Chief Scientific Officer

Epify Strengthens Management Team by Appointing Leander Van Neste as Chief Scientific Officer

Maastricht, The Netherlands, November 7, 2019 -- Epify BV is a recently established biotechnology company that translates sound epigenetic biomarker discoveries into clinical practice to...
Read more
Official launch of OHMX.bio, partner for high-throughput OMICS solutions

Official launch of OHMX.bio, partner for high-throughput OMICS solutions

Ghent, 14 October 2019. Novalis and Ghent University are proud to release OHMX.bio (www.ohmx.bio), the sixth instalment in Novalis’ portfolio of biotechnology and life sciences...
Read more
Novalis participates in financing round of FERTIGA for further expansion of the Corona Test

Novalis participates in financing round of FERTIGA for further expansion of the Corona Test

Ghent, Belgium, 09 Oct 2019. Fertiga, the Belgian female fertility company, announces the closure of its first financing round together with Novalis Biotech Incubation and...
Read more
Go to the News page

Novalis Portfolio

Here are a few of our Portfolio companies.


Fertiga

Fertiga (www.fertiga.com) is a spin-off from Vrije Universiteit Brussel (VUB) on the basis of research carried out over the past 10 years within the VUB and University hospital of Brussels (UZ Brussels). Our objective is to become a major player in improving fertility treatment outcomes. We improve efficiency of IVF by analysis of gene expressions in cells surrounding the egg cell. Our goal is to reach ‘one child with one try’.

Epify

Epigenetic Biomarkers for Cancer Diagnosis and Personalized Treatment

Epify develops epigenetic biomarkers which control gene activity and are implicated in a wide range of cancers, driving and influencing the course of the disease. Using these biomarkers, Epify aims to drive earlier detection and more accurate diagnosis, facilitating personalized oncology and a better prognosis for cancer patients.

See more on www.epify.nl

Doc.ai

Doc.ai wants to break down data silos and transform healthcare with the power of artificial intelligence. End users can collect all their medical information in the doc.ai app. By agreeing to also share their anonymized data with researchers, they feed the machine learning capacities of the platform, getting more accurate results and accelerating medical research to the benefit of generations to come.
Watch the video about doc.ai

myNEO

myNEO identifies and evaluates patient-specific mutant peptides that are present (DNA) and expressed (RNA), but absent in the patient’s germline.
This analysis is the first step in any personalised immunotherapy.

ohmx.bio

OhmX.bio is a spin-off initiative @ the Ghent University offering R&D through cutting-edge technologies to help our customers resolve their biological questions, providing a full trajectory from sample preparation to data analysis of the results. We offer next generation wet-lab solutions to our customers in the field of transcriptomics, translatomics, proteomics and epigenetics.

BioLizard

BioLizard (Lizard.Bio) is founded to provide bioinformatics solutions for customers in biotech, pharma and academia. As life science research is rapidly evolving into a more data-driven field, there is a niche and a high demand for this type of applications. Lizards adapt to their biological environment. Likewise, we strive towards offering state-of-the-art bioinformatics, statistics and machine learning solutions to help solve biological questions by adapting to the needs and data of our customers.